| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From The Breast Service (Department of Surgery), Division of Nuclear Medicine (Department of Radiology), Department of Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York.
Correspondence: Address correspondence and reprint requests to: Hiram S. Cody III. MD, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, NY, NY 10021; Fax: 212-794-5812; E-mail: codyh{at}mskcc.org
Background: The hypothesis that sentinel lymph node (SLN) mapping in breast cancer patients is optimized by combining blue dye and isotope is reasonable and intuitive. Despite this, few studies examine in detail the factors contributing to the success of these techniques, either individually or in combination.
Methods: During a time period of 21/2 years, 1000 consecutive patients at Memorial Sloan-Kettering Cancer Center had SLN mapping performed by using both blue dye and isotope, with preoperative lymphoscintigraphy (LSG). Among the 966 patients with invasive cancer, 12 variables were examined for their correlation with the success of SLN localization by blue dye, by isotope, and by the combined method, using univariate and multivariate models.
Results: By univariate analysis, blue dye success was more frequent in association with: a positive LSG (P = .02), age 
60 (P < .0005), a previous surgical biopsy (P = .03), and an outer quadrant tumor (P < .0005). Isotope success was more frequent with a positive LSG (P < .0005), age 60 (P = .004), and intradermal isotope injection (P < .0005). Combined (dye and/or isotope) success was more frequent when there was a positive LSG (P < .0005), age 60 (P = .006) and intradermal isotope injection (P < .0005).
In multivariate analysis, blue dye success remained uniquely associated with outer quadrant tumor location (P < .0005), and isotope success was uniquely associated with intradermal isotope injection (P = .012). Combined success was more frequent with a positive LSG (P < .0005), age 60 (P = .033), and intradermal isotope injection (P = .003).
Conclusions: The five variables associated with successful SLN localization by blue dye or by isotope overlap but are not identical. Only three of these, intradermal isotope injection, a positive LSG, and age <60, predicted success by the dye-isotope combination in the multivariate model. Dye and isotope complement each other, and SLN biopsy for breast cancer should use both.
Key Words: Lymphoscintigraphy • —Sentinel node biopsy— • Breast cancer surgery.
This article has been cited by other articles:
 |
|
 |
|
  T. G. Zogakis, R. Essner, H.-j. Wang, L. J. Foshag, and D. L. Morton Natural History of Melanoma in 773 Patients with Tumor-Negative Sentinel Lymph Nodes Ann. Surg. Oncol., May 1, 2007; 14(5): 1604 - 1611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Pavlista, O. Eliska, M. Duskova, M. Zikan, and D. Cibula Localization of the Sentinel Node of the Upper Outer Breast Quadrant in the Axillary Quadrants Ann. Surg. Oncol., February 1, 2007; 14(2): 633 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Govindarajan, D. M. Ghazarian, D. R. McCready, and W. L. Leong Histological Features of Melanoma Sentinel Lymph Node Metastases Associated with Status of the Completion Lymphadenectomy and Rate of Subsequent Relapse Ann. Surg. Oncol., February 1, 2007; 14(2): 906 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. I. Nowecki, P. Rutkowski, A. Nasierowska-Guttmejer, and W. Ruka Survival Analysis and Clinicopathological Factors Associated With False-Negative Sentinel Lymph Node Biopsy Findings in Patients with Cutaneous Melanoma Ann. Surg. Oncol., December 1, 2006; 13(12): 1655 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Povoski, J. O. Olsen, D. C. Young, J. Clarke, W. E. Burak, M. J. Walker, W. E. Carson, L. D. Yee, D. M. Agnese, R. V. Pozderac, et al. Prospective Randomized Clinical Trial Comparing Intradermal, Intraparenchymal, and Subareolar Injection Routes for Sentinel Lymph Node Mapping and Biopsy in Breast Cancer Ann. Surg. Oncol., November 1, 2006; 13(11): 1412 - 1421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Wilke, L. M. McCall, K. E. Posther, P. W. Whitworth, D. S. Reintgen, A. M. Leitch, S. G. A. Gabram, A. Lucci, C. E. Cox, K. K. Hunt, et al. Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group Trial Ann. Surg. Oncol., April 1, 2006; 13(4): 491 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Lyman, A. E. Giuliano, M. R. Somerfield, A. B. Benson III, D. C. Bodurka, H. J. Burstein, A. J. Cochran, H. S. Cody III, S. B. Edge, S. Galper, et al. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer J. Clin. Oncol., October 20, 2005; 23(30): 7703 - 7720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Degnim, K. Oh, V. M. Cimmino, K. M. Diehl, A. E. Chang, L. A. Newman, and M. S. Sabel Is Blue Dye Indicated for Sentinel Lymph Node Biopsy in Breast Cancer Patients With a Positive Lymphoscintigram? Ann. Surg. Oncol., September 1, 2005; 12(9): 712 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Zogakis, R. Essner, H.-j. Wang, R. R. Turner, Y. T. Takasumi, R. L. Gaffney, J. H. Lee, and D. L. Morton Melanoma Recurrence Patterns After Negative Sentinel Lymphadenectomy Arch Surg, September 1, 2005; 140(9): 865 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Mendez, J. V. Fey, H. Cody, P. I. Borgen, and L. M. Sclafani Can Sentinel Lymph Node Biopsy Be Omitted in Patients With Favorable Breast Cancer Histology? Ann. Surg. Oncol., January 1, 2005; 12(1): 24 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chagpar, R. C. Martin III, C. Chao, S. L. Wong, M. J. Edwards, T. Tuttle, and K. M. McMasters Validation of Subareolar and Periareolar Injection Techniques for Breast Sentinel Lymph Node Biopsy Arch Surg, June 1, 2004; 139(6): 614 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. King, J. V. Fey, K. J. Van Zee, A. S. Heerdt, M. L. Gemignani, E. R. Port, L. Sclafani, V. Sacchini, J. A. Petrek, H. S. Cody III, et al. A Prospective Analysis of the Effect of Blue-Dye Volume on Sentinel Lymph Node Mapping Success and Incidence of Allergic Reaction in Patients With Breast Cancer Ann. Surg. Oncol., May 1, 2004; 11(5): 535 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Pawlik, M. I. Ross, and J. E. Gershenwald Lymphatic Mapping in the Molecular Era Ann. Surg. Oncol., April 1, 2004; 11(4): 362 - 374. [Full Text] [PDF]
|
|
|
|
 |
|
 C A Murray, W L Leong, D R McCready, and D M Ghazarian Histopathological patterns of melanoma metastases in sentinel lymph nodes J. Clin. Pathol., January 1, 2004; 57(1): 64 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Krynyckyi, C. K. Kim, M. R. Goyenechea, P. T. Chan, Z.-Y. Zhang, and J. Machac Clinical Breast Lymphoscintigraphy: Optimal Techniques for Performing Studies, Image Atlas, and Analysis of Images RadioGraphics, January 1, 2004; 24(1): 121 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Liberman Lymphoscintigraphy for Lymphatic Mapping in Breast Carcinoma Radiology, August 1, 2003; 228(2): 313 - 315. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sprung, M. J. Tully, and A. Ziser Anaphylactic Reactions to Isosulfan Blue Dye During Sentinel Node Lymphadenectomy for Breast Cancer Anesth. Analg., April 1, 2003; 96(4): 1051 - 1053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Balch, M. S. Roh, K. I. Bland, M. F. Brennan, E. M. Copeland III, D. L. Morton, J. E. Niederhuber, and R. E. Pollock Annals of Surgical Oncology Impact Factor/Rating Has Dramatically Increased Ann. Surg. Oncol., January 1, 2003; 10(1): 1 - 3. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bonnema and C. J. H. van de Velde Sentinel lymph node biopsy in breast cancer Ann. Onc., October 1, 2002; 13(10): 1531 - 1537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Montgomery, A. C. Thorne, K. J. Van Zee, J. Fey, A. S. Heerdt, M. Gemignani, E. Port, J. Petrek, H. S. Cody III, and P. I. Borgen Isosulfan Blue Dye Reactions During Sentinel Lymph Node Mapping for Breast Cancer Anesth. Analg., August 1, 2002; 95(2): 385 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. I. Bland Utilization of Sentinel Lymph Node Mapping to Determine Pathologic Outcomes for Patients Receiving Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Ann. Surg. Oncol., April 1, 2002; 9(3): 217 - 219. [Full Text] [PDF]
|
|
|
|
|
|
A. R. Miller, V. E. Thomason, I-T. Yeh, A. Alrahwan, F. E. Sharkey, J. Stauffer, P. M. Otto, C. McKay, M. S. Kahlenberg, W. T. Phillips, et al. Analysis of Sentinel Lymph Node Mapping With Immediate Pathologic Review in Patients Receiving Preoperative Chemotherapy for Breast Carcinoma Ann. Surg. Oncol., April 1, 2002; 9(3): 243 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Nathanson, D. L. Wachna, D. Gilman, K. Karvelis, S. Havstad, and J. Ferrara Pathways of Lymphatic Drainage From the Breast Ann. Surg. Oncol., December 1, 2001; 8(10): 837 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. McCarter, H. Yeung, S. Yeh, J. Fey, P. I. Borgen, and H. S. Cody III Localization of the Sentinel Node in Breast Cancer: Identical Results With Same-Day and Day-Before Isotope Injection Ann. Surg. Oncol., September 1, 2001; 8(8): 682 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C.G. Martin, J. Fey, H. Yeung, P. I. Borgen, and H. S. Cody III Highest Isotope Count Does Not Predict Sentinel Node Positivity in All Breast Cancer Patients Ann. Surg. Oncol., August 1, 2001; 8(7): 592 - 597. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
